SOPHiA GENETICS Statistics
Total Valuation
SOPHiA GENETICS has a market cap or net worth of $611.60 million. The enterprise value is $578.99 million.
| Market Cap | 611.60M |
| Enterprise Value | 578.99M |
Important Dates
The last earnings date was Tuesday, November 3, 2026, before market open.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SOPHiA GENETICS has 85.66 million shares outstanding. The number of shares has increased by 11.27% in one year.
| Current Share Class | 85.66M |
| Shares Outstanding | 85.66M |
| Shares Change (YoY) | +11.27% |
| Shares Change (QoQ) | +15.81% |
| Owned by Insiders (%) | 8.35% |
| Owned by Institutions (%) | 44.77% |
| Float | 66.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.72 |
| Forward PS | 5.40 |
| PB Ratio | 8.94 |
| P/TBV Ratio | 18.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.29, with a Debt / Equity ratio of 0.89.
| Current Ratio | 2.29 |
| Quick Ratio | 2.01 |
| Debt / Equity | 0.89 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.20 |
Financial Efficiency
Return on equity (ROE) is -125.67% and return on invested capital (ROIC) is -36.34%.
| Return on Equity (ROE) | -125.67% |
| Return on Assets (ROA) | -26.46% |
| Return on Invested Capital (ROIC) | -36.34% |
| Return on Capital Employed (ROCE) | -56.78% |
| Weighted Average Cost of Capital (WACC) | 10.10% |
| Revenue Per Employee | $219,210 |
| Profits Per Employee | -$195,492 |
| Employee Count | 415 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 4.41 |
Taxes
In the past 12 months, SOPHiA GENETICS has paid $250,000 in taxes.
| Income Tax | 250,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +57.97% in the last 52 weeks. The beta is 1.09, so SOPHiA GENETICS's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | +57.97% |
| 50-Day Moving Average | 7.70 |
| 200-Day Moving Average | 5.99 |
| Relative Strength Index (RSI) | 46.98 |
| Average Volume (20 Days) | 662,462 |
Short Selling Information
The latest short interest is 1.00 million, so 1.17% of the outstanding shares have been sold short.
| Short Interest | 1.00M |
| Short Previous Month | 1.12M |
| Short % of Shares Out | 1.17% |
| Short % of Float | 1.52% |
| Short Ratio (days to cover) | 1.35 |
Income Statement
In the last 12 months, SOPHiA GENETICS had revenue of $90.97 million and -$81.13 million in losses. Loss per share was -$1.09.
| Revenue | 90.97M |
| Gross Profit | 60.44M |
| Operating Income | -73.70M |
| Pretax Income | -80.88M |
| Net Income | -81.13M |
| EBITDA | -71.69M |
| EBIT | -73.70M |
| Loss Per Share | -$1.09 |
Balance Sheet
The company has $93.65 million in cash and $61.04 million in debt, with a net cash position of $32.61 million or $0.38 per share.
| Cash & Cash Equivalents | 93.65M |
| Total Debt | 61.04M |
| Net Cash | 32.61M |
| Net Cash Per Share | $0.38 |
| Equity (Book Value) | 68.43M |
| Book Value Per Share | 0.80 |
| Working Capital | 70.71M |
Cash Flow
In the last 12 months, operating cash flow was -$40.43 million and capital expenditures -$1.09 million, giving a free cash flow of -$41.52 million.
| Operating Cash Flow | -40.43M |
| Capital Expenditures | -1.09M |
| Depreciation & Amortization | 2.02M |
| Net Borrowing | -2.30M |
| Free Cash Flow | -41.52M |
| FCF Per Share | -$0.48 |
Margins
Gross margin is 66.43%, with operating and profit margins of -81.02% and -89.18%.
| Gross Margin | 66.43% |
| Operating Margin | -81.02% |
| Pretax Margin | -88.91% |
| Profit Margin | -89.18% |
| EBITDA Margin | -78.80% |
| EBIT Margin | -81.02% |
| FCF Margin | n/a |
Dividends & Yields
SOPHiA GENETICS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -11.27% |
| Shareholder Yield | -11.27% |
| Earnings Yield | -15.21% |
| FCF Yield | -6.79% |
Analyst Forecast
The average price target for SOPHiA GENETICS is $9.75, which is 36.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.75 |
| Price Target Difference | 36.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 25.92% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SOPHiA GENETICS has an Altman Z-Score of -2.67 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.67 |
| Piotroski F-Score | 2 |